Monthly Injections Help 90% of Severe Asthma Patients Reduce Steroid Use

A new study published in Lancet Respiratory Medicine reveals that monthly injections of Tezepelumab significantly aid patients with severe asthma in reducing their reliance on corticosteroids. The findings, released on March 15, 2024, indicate that approximately 90% of participants managed to lower their corticosteroid dosage, with half completely discontinuing these medications.

The research was conducted with funding from AstraZeneca, a leading pharmaceutical company. According to the Asthma and Allergy Foundation of America, over 28 million Americans are affected by asthma, a chronic condition characterized by inflammation and swelling in the airways. This condition leads to the narrowing of air passages, which can cause significant breathing difficulties.

Corticosteroids are commonly prescribed to control airway inflammation and alleviate asthma symptoms. However, these medications come with serious health risks, including osteoporosis, diabetes, and a heightened vulnerability to infections. While corticosteroids are typically taken daily, Tezepelumab is administered via injection once every four weeks, offering a potentially less burdensome alternative for patients.

Study Highlights and Patient Impact

In the Phase 3 trial, researchers noted that not only did the use of Tezepelumab reduce steroid dependence, but it also led to considerable improvements in asthma symptoms and lung function. The authors of the study highlighted that the majority of patients experienced fewer emergency visits and hospitalizations related to asthma. Positive results were evident as early as two weeks into the treatment, with benefits lasting throughout the study duration.

“Overall quality of life for patients significantly improved,” the authors stated. This finding is particularly relevant given the chronic nature of asthma and the ongoing challenges faced by those living with the condition.

The implications of this research extend beyond individual health benefits. With a substantial portion of asthma patients relying on corticosteroids, reducing their usage could lessen the long-term health risks associated with these medications and improve overall patient outcomes.

As the medical community continues to explore effective treatments for asthma, the results from this study provide hope for patients seeking alternatives to daily corticosteroid use. Tezepelumab’s potential to enhance quality of life while minimizing dependency on more harmful medications marks a significant advancement in asthma management strategies.